Advertisement

Health-Related Quality of Life Issues

  • John T. Wei
  • David Miller
Chapter
  • 140 Downloads
Part of the Current Clinical Urology book series (CCU)

Abstract

The physician’s primary responsibility in caring for a prostate cancer patient is to address the patient’s concerns regarding treatment and prognosis. Fortunately, the prognosis for prostate cancer, particularly for localized disease, is often favorable. Given that most patients will have survival measured in years, prostate cancer can reasonably be characterized as a “chronic” disease of aging (1). As with most chronic diseases, health-related quality of life (HRQOL) becomes a primary concern for the patient, and an appreciation of HRQOL outcomes plays a role in treatment decision making. The use of HRQOL as an endpoint for treatment has been increasingly emphasized in urologic and oncologic clinical trials as a means to differentiate between various therapies and to track disease progression (2–6). This chapter introduces state of the art concepts underlying the assessment of HRQOL, gives guidelines for selecting HRQOL instruments, and summarizes the contemporary literature related to prostate cancer HRQOL.

Keywords

Urinary Incontinence Radical Prostatectomy Radiat Oncol Biol Phys Localize Prostate Cancer Advanced Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975–980.PubMedCrossRefGoogle Scholar
  2. 2.
    Staquet MJ, Hays RD, Fayers PM. Quality of Life Assessment in Clinical Trials—Methods and Practice. Oxford University Press, New York, 1999.Google Scholar
  3. 3.
    Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129–135.PubMedCrossRefGoogle Scholar
  4. 4.
    Litwin MS, Pasta DJ, Yu J, et al. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2000; 164: 1973–1977.PubMedCrossRefGoogle Scholar
  5. 5.
    Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92: 1582–1592.PubMedCrossRefGoogle Scholar
  6. 6.
    Schapira MM, Lawrence WF, Katz DA, et al. Effect of treatment on quality of life among men with clinically localized prostate cancer. Medical Care 2001; 39: 243–253.PubMedCrossRefGoogle Scholar
  7. 7.
    Ware JE Jr, Brook RH, Davies AR, et al. Choosing measures of health status for individuals in general populations. Am J Public Health 1981; 71: 620–625.PubMedCrossRefGoogle Scholar
  8. 8.
    Barry MJ. Quality of life and prostate cancer treatment. J Urol 1999; 162: 407.PubMedCrossRefGoogle Scholar
  9. 9.
    Browne JP. Health-related quality-of-life studies in urology: conceptual and methodological considerations. World J Urol 1999; 17: 193–198.PubMedCrossRefGoogle Scholar
  10. 10.
    Litwin MS. Examining health-related quality of life in men treated for prostate cancer. World J Urol 1999; 17: 205–210.PubMedCrossRefGoogle Scholar
  11. 11.
    Sloan JA, Varricchio C. Quality of life endpoints in prostate chemoprevention trials. Urology 2001; 57: 235–240.PubMedCrossRefGoogle Scholar
  12. 12.
    Moinpour CM, Hayden KA, Thompson IM, et al. Quality of life assessment in Southwest Oncology Group trials. Oncology 1989; 4: 79–84.Google Scholar
  13. 13.
    Moinpour CM, Lovato LC, Thompson IM Jr, et al. Profile of men randomized to the Prostate Cancer Prevention Trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors. J Clin Oncol 2000; 18: 1942–1953.PubMedGoogle Scholar
  14. 14.
    Moinpour CM, Lovato LC. Ensuring the quality of quality of life data: the Southwest Oncology Group experience. Stat Med 1998; 17: 641–651.PubMedCrossRefGoogle Scholar
  15. 15.
    Macdonagh R. Quality of life and its assessment in urology. Br J Urol 1996; 78: 485–496.PubMedCrossRefGoogle Scholar
  16. 16.
    Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996; 334: 835–840.PubMedCrossRefGoogle Scholar
  17. 17.
    Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995; 273: 59–65.PubMedCrossRefGoogle Scholar
  18. 18.
    Streiner DL, Norman J. Health Measurement Scales. Oxford University Press, New York, 1995.Google Scholar
  19. 19.
    Yarbro CH, Ferrans CE. Quality of life of patients with prostate cancer treated with surgery or radiation therapy. Oncol Nurs Forum 1998; 25: 685–693.PubMedGoogle Scholar
  20. 20.
    Lubeck DP, Litwin MS, Henning JM, et al. Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database. Quality Life Res 1997; 6: 385–392.CrossRefGoogle Scholar
  21. 21.
    Litwin MS, Shpall AI, Dorey F, et al. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 1998; 21: 327–332.PubMedCrossRefGoogle Scholar
  22. 22.
    Smith DS, Carvalhal GF, Schneider K, et al. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer 2000; 88: 1454–1463.PubMedCrossRefGoogle Scholar
  23. 23.
    Litwin MS, Melmed GY, Nakazon T. Life after radical prostatectomy: a longitudinal study. J Urol 2001; 166: 587–592.PubMedCrossRefGoogle Scholar
  24. 24.
    Fowler FJ Jr, Barry MJ, Lu-Yao G, et al. Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology 1995; 45: 1007–1013.PubMedCrossRefGoogle Scholar
  25. 25.
    Braslis KG, Santa-Cruz C, Brickman AL, et al. Quality of life 12 months after radical prostatectomy. Br J Urol 1995; 75: 48–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Bacon CG, Giovannucci E, Testa M, et al. The association of treatment-related symptoms-with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 2002; 94: 862–871.PubMedCrossRefGoogle Scholar
  27. 27.
    Knight SJ, Chmiel JS, Kuzel T, et al. Quality of life in metastatic prostate cancer among men of lower socioeconomic status: feasibility and criterion related validity of 3 measures. J Urol 1998; 160: 1765–1769.PubMedCrossRefGoogle Scholar
  28. 28.
    Kim SP, Bennett CL, Chan C, et al. QOL and outcomes research in prostate cancer patients with low socioeconomic status. Oncology (Huntington) 1999; 13: 823–832.Google Scholar
  29. 29.
    Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920–928.PubMedCrossRefGoogle Scholar
  30. 30.
    Schag CA, Ganz PA, Wing DS, et al. Quality of life in adult survivors of lung, colon and prostate cancer. Quality of Life Res 1994; 3: 127–141.CrossRefGoogle Scholar
  31. 31.
    Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Medical Care 1998; 36: 1002–1012.PubMedCrossRefGoogle Scholar
  32. 32.
    Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899–905.PubMedCrossRefGoogle Scholar
  33. 33.
    Giesler RB, Miles BJ, Cowen ME, et al. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Quality of Life Res 2000; 9: 645–665.CrossRefGoogle Scholar
  34. 34.
    Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998; 159: 1988–1992.PubMedCrossRefGoogle Scholar
  35. 35.
    Knight SJ, Chmiel JS, Sharp LK, et al. Spouse ratings of quality of life in patients with metastatic prostate cancer of lower socioeconomic status: an assessment of feasibility, reliability, and validity. Urology 2001; 57: 275–280.PubMedCrossRefGoogle Scholar
  36. 36.
    Sneeuw KC, Albertsen PC, Aaronson NK. Comparison of patient and spouse assessments of health related quality of life in men with metastatic prostate cancer. J Urol 2001; 165: 478–482.PubMedCrossRefGoogle Scholar
  37. 37.
    Kielb S, Dunn RL, Rashid MG, et al. Assessment of early continence recovery after radical prostatectomy: patient reported symptoms and impairment. J Urol 2001; 166: 958–961.PubMedCrossRefGoogle Scholar
  38. 38.
    Melmed GY, Kwan L, Reid K, et al. Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology 2002; 59: 103–109.PubMedCrossRefGoogle Scholar
  39. 39.
    Lubeck DP, Kim H, Grossfeld G, et al. Health related quality of life differences between black and white men with prostate cancer: data from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2001; 166: 2281–2285.PubMedCrossRefGoogle Scholar
  40. 40.
    Penson DF, Stoddard ML, Pasta DJ, et al. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol 2001; 54: 350–358.PubMedCrossRefGoogle Scholar
  41. 41.
    Eton DT, Lepore SJ, Helgeson VS Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer 2001; 92: 1451–1459.PubMedCrossRefGoogle Scholar
  42. 42.
    Ellison LM, Heaney JA, Birkmeyer JD. Trends in the use of radical prostatectomy for treatment of prostate cancer. Effect Clin Pract 1999; 2: 228–233.Google Scholar
  43. 43.
    Mettlin C. Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974–1993. Prostate 1997; 32: 221–226.PubMedCrossRefGoogle Scholar
  44. 44.
    Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20: 557–566.PubMedCrossRefGoogle Scholar
  45. 45.
    Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790–796.PubMedCrossRefGoogle Scholar
  46. 46.
    Walsh PC. Radical retropubic prostatectomy with reduced morbidity: an anatomic approach. NCI Monogr 1988; 133–137.Google Scholar
  47. 47.
    Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354–360.PubMedCrossRefGoogle Scholar
  48. 48.
    Wei JT, Dunn RL, Marcovich R, et al. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 2000; 164: 744–748.PubMedCrossRefGoogle Scholar
  49. 49.
    Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical prostatectomy [Review]. J Urol 1996; 156: 1707–1713.PubMedCrossRefGoogle Scholar
  50. 50.
    Talcott JA, Rieker P, Propert KJ, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997; 89: 1117–1123.PubMedCrossRefGoogle Scholar
  51. 51.
    Scardino PT, Kim ED. Rationale for and results of nerve grafting during radical prostatectomy. Urology 2001; 57: 1016–1019.PubMedCrossRefGoogle Scholar
  52. 52.
    Kim ED, Scardino PT, Kadmon D, et al. Interposition sural nerve grafting during radical retropubic prostatectomy. Urology 2001; 57: 211–216.PubMedCrossRefGoogle Scholar
  53. 53.
    Kim ED, Nath R, Kadmon D, et al. Bilateral nerve graft during radical retropubic prostatectomy: 1- year followup. J Urol 2001; 165: 1950–1956.PubMedCrossRefGoogle Scholar
  54. 54.
    Kim ED, Nath R, Slawin KM, et al. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology 2001; 58: 983–987.PubMedCrossRefGoogle Scholar
  55. 55.
    Pasticier G, Rietbergen JB, Guillonneau B, et al. Robotically assisted laparoscopic radical prostatectomy: feasibility study in men. Eur Urol 2001; 40: 70–74.PubMedCrossRefGoogle Scholar
  56. 56.
    Guillonneau B, Vallancien G. Laparoscopic radical prostatectomy: the Montsouris technique. J Urol 2000; 163: 1643–1649.PubMedCrossRefGoogle Scholar
  57. 57.
    Guillonneau B, Vallancien G. Laparoscopic radical prostatectomy: the Montsouris experience. J Urol 2000; 163: 418–422.PubMedCrossRefGoogle Scholar
  58. 58.
    Olsson LE, Salomon L, Nadu A, et al. Prospective patient-reported continence after laparoscopic radical prostatectomy. Urology 2001; 58: 570–572.PubMedCrossRefGoogle Scholar
  59. 59.
    Sandler HM, Dunn RL, McLaughlin PW, et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000; 48: 629–633.PubMedCrossRefGoogle Scholar
  60. 60.
    Michalski JM, Winter K, Purdy JA, et al. Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Semin Radiat Oncol 2002; 12 (1 suppl 1): 75–80.PubMedCrossRefGoogle Scholar
  61. 61.
    Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267–272.PubMedCrossRefGoogle Scholar
  62. 62.
    Hanlon AL, Watkins BD, Peter R, et al. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001; 49: 51–59.PubMedCrossRefGoogle Scholar
  63. 63.
    Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 1998; 51: 991–997.PubMedCrossRefGoogle Scholar
  64. 64.
    Fransson P, Damber JE, Tomic R, et al. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer 2001; 92: 3111–3119.PubMedCrossRefGoogle Scholar
  65. 65.
    Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994; 74: 2520–2532.PubMedCrossRefGoogle Scholar
  66. 66.
    Janda M, Gerstner N, Obermair A, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer 2000; 89: 1322–1328.PubMedCrossRefGoogle Scholar
  67. 67.
    Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000; 46: 391–402.PubMedCrossRefGoogle Scholar
  68. 68.
    Hamilton AS, Stanford JL, Gilliland FD, et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 2517–2526.PubMedGoogle Scholar
  69. 69.
    Caffo O, Fellin G, Graffer U, et al. Assessment of quality of life after radical radiotherapy for prostate cancer. Br J Urol 1996; 78: 557–563.PubMedCrossRefGoogle Scholar
  70. 70.
    Lee WR, McQuellon RP, Harris-Henderson K, et al. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46: 77–81.PubMedCrossRefGoogle Scholar
  71. 71.
    Egawa S, Shimura S, Irie A, et al. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol 2001; 31: 541–547.PubMedCrossRefGoogle Scholar
  72. 72.
    Talcott JA, Clark JA, Stark PC, et al. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001; 166: 494–499.PubMedCrossRefGoogle Scholar
  73. 73.
    Hollenbeck BK, Dunn RL, Wei JT, et al. Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology 2002; 59: 480–484.PubMedCrossRefGoogle Scholar
  74. 74.
    Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002; 94: 430–437.PubMedCrossRefGoogle Scholar
  75. 75.
    Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Urology 2001; 58 (suppl): 94–100.PubMedCrossRefGoogle Scholar
  76. 76.
    Davis JW, Kuban DA, Lynch DF, et al. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001; 166: 947.PubMedCrossRefGoogle Scholar
  77. 77.
    Lee WR, McQuellon RP, Case LD, et al. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol 1999; 162: 403–406.PubMedCrossRefGoogle Scholar
  78. 78.
    Lee WR, Hall MC, McQuellon RP, et al. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 614–623.PubMedCrossRefGoogle Scholar
  79. 79.
    Potosky AL, Harlan LC, Stanford JL, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 1999; 91: 1719–1724.PubMedCrossRefGoogle Scholar
  80. 80.
    Litwin MS, Lubeck DP, Spitalny GM, et al. Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer 2002; 95: 54–60.PubMedCrossRefGoogle Scholar
  81. 81.
    Bacon CG, Giovannucci E, Testa M, et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001; 166: 1804–1810.PubMedCrossRefGoogle Scholar
  82. 82.
    Albertsen PC, Aaronson NK, Muller MJ, et al. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997; 49: 207–216.PubMedCrossRefGoogle Scholar
  83. 83.
    Litwin MS, Lubeck DP, Stoddard ML, et al. Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol 2001; 165: 871–875.PubMedCrossRefGoogle Scholar
  84. 84.
    Fowler FJ Jr, McNaughton CM, Walker CE, et al. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002; 95: 287–295.PubMedCrossRefGoogle Scholar
  85. 85.
    Pietrow PK, Parekh DJ, Smith JA Jr, et al. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. J Urol 2001; 166: 2286–2290.PubMedCrossRefGoogle Scholar
  86. 86.
    Lim AJ, Brandon AH, Fiedler J, et al. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995; 154: 1420–1425.PubMedCrossRefGoogle Scholar
  87. 87.
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570–579.PubMedGoogle Scholar
  88. 88.
    Da Silva FC, Reis E, Costa T, et al. Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group. Cancer 1993; 71: 1138–1142.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • John T. Wei
  • David Miller

There are no affiliations available

Personalised recommendations